Grant of Options
27 September 2018
Concepta plc (AIM:CPT), the UK healthcare company and developer of a proprietary product targeted at the mobile health market and with a primary focus on women's fertility today announces that share options over 9,409,834 ordinary shares of the Company (representing approximately 5% of the issued ordinary share capital) have been awarded to Matthew Heaton Walls under the Company's Unapproved Share Option Scheme at an exercise price of 4p per share.
The Options shall time vest as follows:
7,500,000 will time vest over 2 years from the date of commencement of Mr Walls' employment on 17 July 2018 (i.e. all options vested by 17 July 2020)
1,909,834 shares will vest immediately on the mid market closing share price meeting or surpassing £0.07 - 7p/share for at least 5 consecutive days.
Details of the person discharging managerial responsibilities / person closely associated
Matthew Heaton Walls
Reason for the notification
Initial notification /Amendment
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument
Options under the Company's EMI Share Option Scheme
Nature of the transaction
Grant of Options
Price(s) and volume(s)
- Aggregated volume
Date of the transaction
28 September 2018
Place of the transaction
London Stock Exchange, AIM
Tel +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin / Mark Brady
Tel: +44 (0)20 368 3550
Novum Securities (Placing Agent)
+44 (0) 20 7399 9400
Yellow Jersey (Financial PR)
Georgia Colkin / Joe Burgess / Katie Bairsto
Tel: +44 (0) 776 932 5254
Concepta PLC is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on fertility and unexplained infertility† in women.
myLotus is currently the only consumer product which allows both quantitative and qualitative home (self test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus is to help women conceive naturally by identifying their window of fertility and optimal time for conception.
The Company anticipates receiving CE-mark certification for myLotus over the coming months and is preparing its B2C launch in the UK and Europe. The Company has identified a significant global market opportunity with revenue potential of the EU and Chinese unexplained infertility market estimated to be worth c.£600m per annum.
Concepta has also made progress in establishing relationships with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the B2C route in the near future.
†Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.